Mario Cazzola

Italy

Associate Editor at Respiratory Medicine

Featured in: Favicon

resmedjournal.com Favicon

nature.com Favicon

wiley.com

tandfonline.com Favicon

nejm.org

thelancet.com Favicon

ersjournals.com (+1) Favicon

bloodjournal.org Favicon

chestnet.org Favicon

jacionline.org + 8 more

Articles

Novel drug discovery strategies for chronic obstructive pulmonary disease: the latest developments

1 week ago | tandfonline.com | Elena Pistocchini |Mario Cazzola |Paola Rogliani |Luigino Calzetta

ABSTRACTIntroduction The journey from initial drug discovery to approval for respiratory diseases typically spans approximately 10.4 years and cost over $2.8 billion. This intricate process involves five stages: target identification, therapeutic molecule discovery, preclinical testing, clinical trials, and regulatory approval.
Efficacy and safety of long-acting muscarinic antagonists in COPD: a meta-analysis and meta-regression with a focus on aging

Jan 24, 2025 | resmedjournal.com | Elena Pistocchini |Mario Cazzola |Paola Rogliani

KeywordsAgeingCOPDefficacylong-acting muscarinic antagonistmeta-analysismeta-regressionsafetyIntroductionThe global elderly population is increasing rapidly, with projections indicating that individuals aged 65 and over will constitute 20% of the total population by 2030 [1]. In healthy individuals, lung development and function peak at around 25 years of age, stabilize until about 35, and then decline with aging.
Challenges in treating patients with comorbid asthma and bronchiectasis

Jan 21, 2025 | resmedjournal.com | Mario Cazzola

Key words Asthma bronchiectasis overlap treatment Abbreviations ABPA (allergic bronchopulmonary aspergillosis) ACh (acetylcholine) BTS (British Thoracic Society) ERS (European Respiratory Society) ICS (inhaled corticosteroid) FDC (fixed-dose combination) FEV1 (forced expiratory volume in one second) GINA (Global Initiative for Asthma) HDAC-2 (histone deacetylase-2) IL (interleukin) LABA (long-acting beta-agonist) LAMA (long-acting muscarinic antagonist) LTRA (leukotriene receptor antagonist)...
Emerging Anti-Inflammatory COPD Treatments: Potential Cardiovascular Impacts

Nov 21, 2024 | tandfonline.com | Mario Cazzola |Luigino Calzetta |Paola Rogliani |Maria Gabriella Matera

AbstractChronic obstructive pulmonary disease (COPD) is a progressive inflammatory condition often complicated by cardiovascular disease (CVD) due to shared inflammatory pathways. This review explores the cardiovascular impacts of emerging anti-inflammatory therapies in COPD.
β-Blockers and Asthma: Surprising Findings from the FAERS Database

Oct 26, 2024 | resmedjournal.com | Mario Cazzola |Paola Rogliani |Maria Gabriella Matera

KeyWordsAsthmaβ-BlockersCardiovascular DiseasesFood and Drug Administration’s Adverse Event Reporting SystemReporting Odds RatioGet full text accessLog in, subscribe or purchase for full access. References1. Ora J, Cavalli F, Cazzola M. Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits. In: Martínez-García MÁ, Pépin J-L, Cazzola M, eds. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020; pp.
Practical Approaches to Identifying Early Chronic Obstructive Pulmonary Disease

Jun 11, 2024 | touchrespiratory.com | Mario Cazzola |Josuel Ora |Luigino Calzetta |Paola Rogliani

Overview Identifying patients with chronic obstructive pulmonary disease (COPD) at the earliest possible stage can achieve the best symptom control, disease progression and outcomes in COPD. However, in clinical practice, the ability to identify individuals at risk of progressing from early disease to clinically severe disease remains limited.
Understanding evidence from randomised controlled trials and meta-analyses: a comparative overview

May 30, 2024 | erj.ersjournals.com | Mario Cazzola |Mona Bafadhel |Paola Rogliani

Conflict of interest: M.
Hyperglycaemia and Chronic Obstructive Pulmonary Disease

Nov 1, 2023 | mdpi.com | Mario Cazzola |Paola Rogliani |Josuel Ora |Luigino Calzetta

1. IntroductionThere is increasing evidence that chronic obstructive pulmonary disease (COPD) and type 2 diabetes mellitus (T2DM) often coexist and the presence of T2DM is associated with a worse prognosis [1]. The mechanistic relationships between these two diseases are complex, multifaceted and poorly understood, but may have implications for treatment strategies. 2.
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?

Aug 17, 2023 | erj.ersjournals.com | Mario Cazzola |Maria Gabriella Matera |Paola Rogliani |Nicola Hanania

FootnotesAuthor contributions: All authors: conceptualisation, supervision and review of the literature. M. Cazzola and N.A. Hanania: writing original draft. C.P. Page, M.G. Matera and P. Rogliani: review and editing of the manuscript. Conflict of interest: M.
Revisiting Asthma Pharmacotherapy: Where Do We Stand and Where Do We Want to Go?

Jul 20, 2023 | erj.ersjournals.com | Mario Cazzola |Maria Gabriella Matera |Paola Rogliani |Nicola Hanania

Thank you for your interest in spreading the word on European Respiratory Society . NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Mario Cazzola

Articles

Novel drug discovery strategies for chronic obstructive pulmonary disease: the latest developments

Efficacy and safety of long-acting muscarinic antagonists in COPD: a meta-analysis and meta-regression with a focus on aging

Challenges in treating patients with comorbid asthma and bronchiectasis

Emerging Anti-Inflammatory COPD Treatments: Potential Cardiovascular Impacts

β-Blockers and Asthma: Surprising Findings from the FAERS Database

Practical Approaches to Identifying Early Chronic Obstructive Pulmonary Disease

Understanding evidence from randomised controlled trials and meta-analyses: a comparative overview

Hyperglycaemia and Chronic Obstructive Pulmonary Disease

Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?

Revisiting Asthma Pharmacotherapy: Where Do We Stand and Where Do We Want to Go?

Contact details

Emails

Socials & Sites